Specifically, we proved that small inhibitors of KIF18A were feasible to suppress the malignant phenotypes of CIN+ colorectal cancer cells, which provided therapeutic evidences for using KIF18A as a novel target in the treatment of CIN+ colorectal cancer. This evidence concerns the gene KIF18A and cervical squamous intraepithelial neoplasia.